Oliver Sartor MD
Director of the Radiopharmaceutical Trials, Chief of the Genitourinary Cancer Malignancy Group, Mayo Clinic, Rochester, MinnesotaDr. Oliver Sartor is a medical oncologist in the Division of Medical Oncology in the Department of Oncology at the Mayo Clinic in Rochester, Minnesota. He serves as Chair of the Genitourinary Cancer Disease Group and the Director of Radiopharmaceutical Clinical Trials for the Mayo Clinic Comprehensive Cancer Center.
Dr. Sartor is an internationally recognized expert in prostate cancer. His medical practice and research have focused on prostate cancer since 1990 when he finished a medical oncology fellowship at the National Cancer Institute (NCI). He has published over 500 peer-reviewed articles, led or co-led multiple national and international clinical studies, including four phase III studies pivotal for FDA approval of drugs for advanced prostate cancer (Quadramet, Xofigo, Pluvicto, and Jevtana). He has lectured widely, and, at last count, has given invited lectures in 33 countries. He is the Medical Oncology Chair of the Genitourinary Cancer Committee of NRG, a national cancer research group.
Disclosures
- Consultant: Advanced Accelerator Applications (AAA); Astellas; AstraZeneca; Bayer; Blue Earth Diagnostics; Bavarian Nordic; Bristol Myers Squibb; Clarity Pharmaceuticals; Clovis; Constellation; Dendreon; EMD Serono; Fusion; Isotopen Technologien Muenchen; Janssen; Merck; Myovant; Myriad; Noria Therapeutics; Novartis; Noxopharm; Progenics; POINT Biopharma; Pfizer; Sanofi; Teneobio; Telix; Theragnostics
- Research funding: Advanced Accelerator Applications; Amgen; AstraZeneca; Bayer; Constellation; Endocyte; Invitae; Janssen; Lantheus; Merck; Progenics; Teneobio
Recent Contributions to PracticeUpdate:
- Key Trials on Advanced Prostate Cancer From ASCO GU 2017
- Longer-Interval Dosing of Zoledronic Acid Effective in Patients With Bone Metastases
- Extended Results of Prostate Cancer Screening in the PLCO Trial: 15-Year Follow-Up
- Liquid Biopsy: Ready to Guide Therapy in Advanced Prostate Cancer?
- Pathological and Biochemical Outcomes Among African-American and Caucasian Men With Low-Risk Prostate Cancer
- Thromboembolic Risk With Androgen Deprivation Therapy in Prostate Cancer
- Genetic Testing in Patients With Relevant Family History in Prostate Cancer
- Inherited Mutations in DNA-Repair Genes in Metastatic Prostate Cancer
- Predictive Biomarkers for Prostate Cancer Treatment Selection
- AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker for Outcomes in Castration-Resistant Prostate Cancer